XOMA (XOMA) Earns “Buy” Rating from HC Wainwright

XOMA (NASDAQ:XOMA)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Thursday, MarketBeat.com reports. They currently have a $49.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 45.92% from the company’s current price.

A number of other equities analysts also recently weighed in on the company. Zacks Investment Research raised XOMA from a “hold” rating to a “strong-buy” rating and set a $33.00 price target on the stock in a research report on Friday, November 10th. Wedbush reissued a “buy” rating and set a $33.00 price target on shares of XOMA in a research report on Tuesday, December 19th. Finally, TheStreet raised XOMA from an “e+” rating to a “c-” rating in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $38.33.

Shares of XOMA (NASDAQ:XOMA) traded up $0.43 during midday trading on Thursday, reaching $33.58. The company’s stock had a trading volume of 191,342 shares, compared to its average volume of 141,686. The firm has a market capitalization of $273.48, a P/E ratio of -10.30 and a beta of 3.17. The company has a current ratio of 3.45, a quick ratio of 3.45 and a debt-to-equity ratio of 3.53. XOMA has a 1 year low of $3.96 and a 1 year high of $37.25.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, November 6th. The biotechnology company reported $1.98 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $2.79. XOMA had a negative return on equity of 1.14% and a negative net margin of 3.51%. equities analysts forecast that XOMA will post -0.08 EPS for the current fiscal year.

In other news, CFO Thomas M. Burns sold 6,983 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $30.99, for a total transaction of $216,403.17. Following the completion of the sale, the chief financial officer now owns 13,538 shares in the company, valued at $419,542.62. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Thomas M. Burns sold 22,222 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $28.69, for a total value of $637,549.18. Following the sale, the senior vice president now owns 13,538 shares of the company’s stock, valued at approximately $388,405.22. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 87,069 shares of company stock valued at $2,517,993. Corporate insiders own 3.02% of the company’s stock.

Large investors have recently modified their holdings of the company. Bank of Montreal Can bought a new stake in shares of XOMA during the fourth quarter worth approximately $138,000. Acadian Asset Management LLC bought a new stake in shares of XOMA during the fourth quarter worth approximately $152,000. OxFORD Asset Management LLP bought a new stake in shares of XOMA during the third quarter worth approximately $543,000. Finally, EAM Investors LLC bought a new stake in shares of XOMA during the third quarter worth approximately $835,000. Institutional investors own 33.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/21/xoma-xoma-earns-buy-rating-from-hc-wainwright.html.

About XOMA

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply